NCT05270928 is a Phase 1 clinical trial of IBI346 in Relapsed/Refractory Multiple Myeloma, sponsored by The First Affiliated Hospital of Soochow University.

Who is sponsoring NCT05270928?

NCT05270928 is sponsored by The First Affiliated Hospital of Soochow University.

What drugs are being tested in NCT05270928?

Interventions in NCT05270928: IBI346.

What condition does NCT05270928 study?

NCT05270928 studies Relapsed/Refractory Multiple Myeloma.

Is NCT05270928 still recruiting?

NCT05270928 is currently completed. Last updated 27 July 2023.

Last reviewed 2023-07-27 · How we verify

NCT05270928

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI346#CIBI346Y001#

Completed Phase 1 Last updated 27 July 2023

What this trial tests

Phase 1 trial testing IBI346 in Relapsed/Refractory Multiple Myeloma in 6 participants. Completed in 29 May 2023.

Timeline

27 April 2022

Primary endpoint
21 December 2022

29 May 2023

Quick facts

Lead sponsor	The First Affiliated Hospital of Soochow University
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	6
Start date	27 April 2022
Primary completion	21 December 2022
Estimated completion	29 May 2023
Sites	1 location across China

Drugs / interventions tested

IBI346 — full drug profile →

Conditions studied

Relapsed/Refractory Multiple Myeloma — all drugs for Relapsed/Refractory Multiple Myeloma →

Sponsor

The First Affiliated Hospital of Soochow University

Who can join

18 and older, any sex, with Relapsed/Refractory Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

An open label, single-arm clinical study evaluating the safety and efficacy of IBI346 infusion in relapsed/refractory multiple myeloma

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting B Cell Maturation Antigen in Patients with Multiple Myeloma: Current Perspectives.
Shrivastava T, Van Rhee F, Al Hadidi S. · · 2023 · cited 10× · PMID 37359353 · DOI 10.2147/ott.s370880
The Current Landscape of Modular CAR T Cells.
Joechner AH, Mach M, Li Z. · · 2025 · PMID 41465327 · DOI 10.3390/ijms262411898
P329G-engager: a universal mix & match antibody-based adaptor platform for cancer immunotherapy.
Surowka M, Darowski D, Hutter-Karakoc I, Claus C, et al · · 2026 · PMID 41402230 · DOI 10.1080/19420862.2025.2602993
P1406: SAFETY AND EFFICACY OF IBI346, A FIRST-IN-CLASS BCMA-TARGETING MODULAR CAR-T CELL THERAPY, FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PRELIMINARY RESULTS FROM TWO PHASE I STUDIES
Fu C, LI C, Wang D, Jin S, et al · · 2023

Verify or expand the search:

Other trials of IBI346

Trials testing the same drug.

NCT05266768 — Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI346#CIBI346Y002# · Phase 1 · unknown

Other recruiting trials for Relapsed/Refractory Multiple Myeloma

Currently open trials in the same condition.

NCT07493135 — A Study of IMV102 in Patients With Relapsed/Refractory Multiple Myeloma · EARLY_PHASE1 · recruiting
NCT07509086 — IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia · Phase 2 · recruiting
NCT06730256 — A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell Leukemia · EARLY_PHASE1 · recruiting
NCT06669247 — A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants · Phase 1, PHASE2 · recruiting
NCT06718270 — a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia · EARLY_PHASE1 · recruiting

Other The First Affiliated Hospital of Soochow University trials

Trials by the same sponsor.

NCT07350863 — U69-CART-Cells For R/R T-ALL · Phase 1 · recruiting
NCT06985498 — Immunotherapy Combined With Auto-HSCT and CD22/CD19 CAR-T Sandwich Strategy for B-ALL · Phase 2 · not yet recruiting
NCT07463651 — MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib · Phase 3 · recruiting
NCT07500753 — A Single-arm, Prospective Study of a Clad-LABU Conditioning Regimen in HSCT for R/R MDS/AML in Elderly Patients · NA · recruiting
NCT07511426 — U96-CAR-T-Cells For R/R B-ALL · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05270928 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The First Affiliated Hospital of Soochow University
Last refreshed: 27 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05270928.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing